Cost-effectiveness of respiratory physiotherapy in COPD

What is the cost-effectiveness of respiratory physiotherapy interventions for people with COPD?

Chronic obstructive pulmonary diseases (COPD) are common, often preventable and treatable diseases, characterised by persistent respiratory symptoms and airflow limitation.

Significant comorbidities may have an impact on morbidity and mortality. In the European Union alone, the direct cost of COPD amounts to 6 percent of the total annual healthcare budget in 2011 (380 billion Euros) and accounts for 42 percent of the total direct cost of treating respiratory diseases.



Curious about the rest of the article?

Sign up as a member of the Anatomy & Physiotherapy Society. 
Check out the benefits of a membership and give it a try today! 
Or have a look at our monthly featured article (free) on our homepage.

Already a member? Login below

Signup for our weekly or monthly newsletter and get notified on updates on the themes you're interested in:

Please enable the javascript to submit this form

Anatomy & Physiotherapy is a joint venture
between SoPhy & Sharing Science

Summaries on Physiotherapy B.V.
Berkenweg 7
Postbus 1161
3800 BD Amersfoort
The Netherlands

Chamber of commerce: 74973738
Bank: NL72ABNA0849809959
V.A.T. number: NL860093530B01

Sharing Science
Rijksweg Zuid 99
6134 AA Sittard
The Netherlands
Chamber of Commerce: 58306862